Jiang, Zhouquan
Wang, Jing
Qin, Yongpeng
Liu, Shanggong
Luo, Bin
Bai, Fan
Wei, Huiyi
Zhang, Shaojuan
Wei, Junjie
Ding, Guoyu
Ma, Long
He, Shu
Chen, Rongjie
Sun, Ying
Chen, Yi
Wang, Lu
Xu, Hao
Wang, Xiangyu
Chen, Gong
Lei, Wenliang
Funding for this research was provided by:
Guangdong Provincial Department of Science and Technology (2018B030332001)
Guangzhou Municipal Science and Technology Bureau (202206060002, 202206060002)
National Natural Science Foundation of China (31970906)
Natural Science Foundation of Guangdong Province (2020A1515010083)
Article History
Received: 17 October 2023
Accepted: 15 January 2024
First Online: 27 January 2024
Declarations
:
: All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangdong Yuan Xi Biotech Co., Ltd. (IACUC No. YXSW-2021–002) and Jinan University (IACUC No. 20210806–03) and were in full compliance with the “Guide for the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Science (est. 2006)” and “The use of nonhuman primates in research of the Institute of Laboratory Animal Science (est. 2006)” to ensure the safety of personnel and animal welfare.
: Not applicable.
: Gong Chen is a co-founder of NeuExcell Therapeutics Inc. The other authors have no conflicts of interest to declare.